Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator

NCT00504842 is registered in ClinicalTrials.gov with ImaRx Therapeutics as lead sponsor.

NCT NCT00504842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator
Lead sponsor
ImaRx Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2006
Completion date
March 31, 2008
Enrollment
72 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke